Used in research and development of immunotherapies targeting the CD40 pathway, this antibody modulates immune activation by binding to CD40, a co-stimulatory protein found on antigen-presenting cells. It is employed in studies related to cancer immunotherapy to enhance anti-tumor immune responses, often in combination with other checkpoint inhibitors. The antibody also supports research in autoimmune diseases and transplant rejection by investigating controlled suppression or activation of immune responses. Its high specificity makes it valuable for in vitro assays, flow cytometry, and preclinical animal models aimed at understanding immune system regulation.